Brief: Quantum Genomics Prepares Launch Of Phase III Study In Treatment Of Resistant Hypertension
17/01/2019 17:26
Jan 17 (Reuters) - QUANTUM GENOMICS SA ALQGC.PA :
* QUANTUM GENOMICS PREPARES FOR LAUNCH OF A PHASE III STUDY
IN THE
TREATMENT OF HIGH BLOOD PRESSURE RESISTANT
Source text for Eikon: ID:nACT56752
Further company coverage: ALQGC.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))
Recent news on Quantum Genomics SA
See all newsBrief: Quantum Genomics Announces Resumption Of Discussions With HealthTech, Terminates Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics Enters Into Exclusive Negotiations With Vistacare Medical
Brief: Quantum Genomics To Reduce Staff; Jean-Philippe Milon Becomes President and CEO
Brief: Quantum Genomics In Talks For New Strategic Project
Brief: Quantum Genomics Announces Lack Of Significant Efficacy For Firibastat In Their Phase Iii Study